…
Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, the United Arab Emirates, Albania, North Macedonia, and Cyprus. The company provides prescription medications, over-the-counter drugs, medical devices, food supplements, nutraceuticals, cosmetics and other healthcare products under the Sky Premium Life and Mediterranation brand names. It offers ASTO-CHOL (Pravastatin), Diorium (Omeprazole), HEART-FREE (Clopidogrel), LIPICHOL (Atorvastatin), Miltus (Donepezil), Newzypra (Olanzapine), PNEUMO-KAST (Montelukast), Sahar (Pioglitazone), VIVALCID (Leucovorin), and Diabit-is (Sitagliptin). In addition, the company offers branded biocides and antiseptic soaps under the C-Sept and C-Scrub brand names; and other pharmaceutical products include Melatonin Spray, used to reduce insomnia and jet lag; Otikon ear drops, which is a Class II medical device in the form of ear drops; and baby foods, such as organic powder milk, pasta with minced meat, whole grain rice cereals, whole grain cereal porridges, and organic rice creams with vanilla milk, as well as pear, carrot and banana purée under the Bio-bebe brand. It serves wholesalers and retail healthcare providers. The company was founded in 2009 and is headquartered in Thessaloniki, Greece.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Public information on Cosmos Health Inc. (NASDAQ: COSM) is limited and filings provide few details about its operations or product lines. The company appears positioned in the healthcare sector and may benefit if management can articulate scalable revenue streams and demonstrate execution on clinical, reimbursement or distribution initiatives that support long-term growth.
Key investment risks include limited disclosure and transparency, an unclear business model and revenue visibility, potential lack of operating history or profitability, and liquidity or financing uncertainty that could constrain execution.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -19.14M | -16.18M | -18.54M | -13.06M | -7.85M |
| Net income | -19.14M | -16.18M | -18.54M | -13.83M | -7.96M |
| Selling general administrative | 15.62M | 11.73M | 25.40M | 12.61M | 11.68M |
| Selling and marketing expenses | 0.15M | 0.35M | - | 0.63M | 0.73M |
| Gross profit | 7.90M | 4.31M | 4.35M | 5.96M | 8.33M |
| Reconciled depreciation | 1.37M | 1.25M | 0.61M | 0.19M | 0.45M |
| Ebit | -16.54M | -15.17M | - | -7.47M | -4.53M |
| Ebitda | -15.17M | -13.92M | - | -9.47M | -4.13M |
| Depreciation and amortization | 1.37M | 1.25M | - | -2.00M | 0.41M |
| Operating income | -16.70M | -15.54M | -21.83M | -7.47M | -4.53M |
| Other operating expenses | 81.98M | 69.97M | - | 57.82M | 60.77M |
| Interest expense | 2.62M | 1.01M | 0.87M | 3.97M | 3.58M |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.78M | 0.11M |
| Interest income | 0.40M | 0.41M | 0.66M | 0.24M | 0.05M |
| Net interest income | -2.23M | -0.61M | -0.20M | -3.73M | -3.53M |
| Income tax expense | - | 6.20M | - | 0.78M | 0.11M |
| Total revenue | 65.27M | 54.43M | 53.38M | 50.35M | 56.24M |
| Total operating expenses | 24.60M | 19.86M | 75.21M | 13.43M | 12.86M |
| Cost of revenue | 57.38M | 50.12M | 49.03M | 44.39M | 47.91M |
| Total other income expense net | -2.44M | -0.64M | 3.49M | -5.58M | -3.31M |
| Net income from continuing ops | -19.14M | -16.18M | -18.54M | -13.83M | -7.96M |
| Net income applicable to common shares | - | - | - | - | -15.59M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 65.48M | 54.31M | 66.01M | 68.04M | 49.43M |
| Intangible assets | 7.52M | 7.71M | 7.63M | 0.66M | 0.44M |
| Other current assets | 12.22M | 4.89M | 6.25M | 5.43M | 1.05M |
| Total liab | 47.05M | 29.78M | 29.97M | 28.38M | 45.05M |
| Total stockholder equity | 18.42M | 24.53M | 36.04M | 39.66M | 4.38M |
| Other current liab | 18.85M | 4.84M | 3.47M | 1.52M | 1.30M |
| Common stock | 0.04M | 0.02M | - | 0.01M | 0.02M |
| Capital stock | 0.04M | 0.02M | 0.02M | 0.38M | 0.02M |
| Retained earnings | -133.17M | -114.02M | -91.64M | -66.23M | -34.35M |
| Good will | 0.05M | 0.05M | 0.05M | 0.05M | 0.05M |
| Other assets | - | -0.00M | - | - | 6.01M |
| Cash | 0.72M | 0.32M | 3.83M | 20.75M | 0.29M |
| Total current liabilities | 38.27M | 25.76M | 24.32M | 21.75M | 29.93M |
| Current deferred revenue | - | - | - | - | 2.94M |
| Net debt | 10.08M | 11.51M | 7.43M | -8.72M | 26.84M |
| Short term debt | 4.79M | 9.76M | - | 8.31M | 13.56M |
| Short long term debt | 13.52M | 9.55M | 8.23M | 8.04M | 13.34M |
| Short long term debt total | 10.79M | 11.82M | - | 12.03M | 27.12M |
| Other stockholder equity | 151.22M | 140.67M | - | 106.64M | 38.86M |
| Property plant equipment | - | - | - | - | 1.88M |
| Total current assets | 38.39M | 25.46M | 36.61M | 56.04M | 40.88M |
| Net tangible assets | - | - | - | - | 3.89M |
| Short term investments | 0.05M | 0.02M | 0.02M | 0.01M | 0.01M |
| Net receivables | 19.63M | 15.88M | 19.76M | 26.40M | 30.14M |
| Long term debt | 5.85M | 1.56M | 3.04M | 2.86M | 12.72M |
| Inventory | 5.78M | 4.36M | 4.79M | 3.45M | 3.15M |
| Accounts payable | 14.62M | 11.16M | 11.91M | 11.92M | 12.13M |
| Accumulated other comprehensive income | 0.33M | -2.13M | - | -1.13M | -0.15M |
| Non currrent assets other | 8.34M | 4.92M | 1.06M | 8.36M | 0.92M |
| Non current assets total | 27.09M | 28.85M | 29.41M | 11.99M | 8.55M |
| Capital lease obligations | 0.60M | 0.71M | 1.16M | 1.12M | 1.06M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -0.80M | 0.00M | -0.02M | -0.83M |
| Change to liabilities | - | - | - | - | 3.82M |
| Total cashflows from investing activities | -2.01M | -0.80M | - | - | -0.83M |
| Net borrowings | 10.47M | 0.55M | -0.02M | - | 7.39M |
| Total cash from financing activities | 14.06M | 5.05M | 12.69M | 35.05M | 7.27M |
| Change to operating activities | - | - | - | - | -4.86M |
| Net income | -19.14M | -16.18M | -25.78M | -13.83M | -7.96M |
| Change in cash | 3.14M | -3.52M | -16.92M | 20.46M | -0.34M |
| Begin period cash flow | 0.32M | 3.83M | 20.75M | 0.29M | 0.63M |
| End period cash flow | 3.46M | 0.32M | 3.83M | 20.75M | 0.29M |
| Total cash from operating activities | -8.45M | -7.72M | -15.64M | -14.87M | -7.10M |
| Issuance of capital stock | 5.42M | 0.65M | 10.00M | 41.28M | 0.25M |
| Depreciation | 1.37M | 1.25M | 0.61M | 0.19M | 0.45M |
| Other cashflows from investing activities | -1.96M | -0.38M | - | - | 0.06M |
| Dividends paid | - | 6.20M | - | -32.00M | -7.63M |
| Change to inventory | -0.83M | 0.15M | -0.89M | -0.49M | -0.09M |
| Change to account receivables | -6.11M | 1.23M | -4.03M | -3.24M | -5.79M |
| Sale purchase of stock | - | -0.10M | -0.10M | 0.00M | -0.38M |
| Other cashflows from financing activities | -1.83M | 10.04M | - | 72.17M | 40.69M |
| Change to netincome | - | - | - | - | 5.96M |
| Capital expenditures | 0.06M | 0.42M | 9.17M | 0.38M | 0.89M |
| Change in working capital | -0.78M | 0.16M | -7.90M | -8.69M | -6.30M |
| Stock based compensation | 2.31M | 1.69M | 0.58M | 0.02M | 5.90M |
| Other non cash items | 7.77M | 5.38M | -0.98M | 6.66M | 1.52M |
| Free cash flow | -8.50M | -8.14M | -24.80M | -15.25M | -7.99M |
Sector: Healthcare Industry: Medical Distribution
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| COSM Cosmos Health Inc. |
-0.06 22.03% |
0.21 | - | 3.87 | 0.38 | 1.32 | 0.56 | -1.60 |
| MCK McKesson Corporation |
4.53 0.43% |
1063.90 | 24.45 | 20.41 | 0.26 | 5.04 | 0.27 | 15.03 |
| COR Cencora Inc. |
-2.51 0.73% |
343.25 | 24.22 | 16.39 | 0.19 | 20.41 | 0.21 | 13.72 |
| CAH Cardinal Health Inc |
-0.93 0.34% |
273.36 | 29.48 | 17.92 | 0.20 | 16.07 | 0.22 | 15.67 |
| HSIC Henry Schein Inc |
0.05 0.06% |
88.46 | 25.89 | 15.08 | 0.72 | 3.14 | 1.00 | 13.43 |
Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, the United Arab Emirates, Albania, North Macedonia, and Cyprus. The company provides prescription medications, over-the-counter drugs, medical devices, food supplements, nutraceuticals, cosmetics and other healthcare products under the Sky Premium Life and Mediterranation brand names. It offers ASTO-CHOL (Pravastatin), Diorium (Omeprazole), HEART-FREE (Clopidogrel), LIPICHOL (Atorvastatin), Miltus (Donepezil), Newzypra (Olanzapine), PNEUMO-KAST (Montelukast), Sahar (Pioglitazone), VIVALCID (Leucovorin), and Diabit-is (Sitagliptin). In addition, the company offers branded biocides and antiseptic soaps under the C-Sept and C-Scrub brand names; and other pharmaceutical products include Melatonin Spray, used to reduce insomnia and jet lag; Otikon ear drops, which is a Class II medical device in the form of ear drops; and baby foods, such as organic powder milk, pasta with minced meat, whole grain rice cereals, whole grain cereal porridges, and organic rice creams with vanilla milk, as well as pear, carrot and banana purée under the Bio-bebe brand. It serves wholesalers and retail healthcare providers. The company was founded in 2009 and is headquartered in Thessaloniki, Greece.
5 Agiou Georgiou Str, Pilea, Thessaloniki, Greece, 55438
312 536 3102
163
| Name | Title | Year Born |
|---|---|---|
| Mr. Grigorios Siokas | Chairman & CEO | 1965 |
| Mr. Georgios Terzis | Chief Financial Officer | 1982 |
| Mr. Pavlos Ignatiades | Chief Operating Officer | 1963 |
| Mr. Demetrios G. Demetriades | Sec. & Independent Director | 1966 |
| Mr. Demetrios G. Demetriades | Secretary & Independent Director | 1966 |
| Mr. Nikolaos Bardakis | Chief Operating Officer | 1969 |
| Mr. Georgios Terzis | Chief Financial Officer | 1983 |
| Mr. Demetrios G. Demetriades | Secretary & Independent Director | 1965 |
| Prof. Dimitrios Trafalis | Head of Oncology | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.